A5083027968- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- MicroRNA in disease regulation
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- Circular RNAs in diseases
- Nutrition, Genetics, and Disease
- RNA modifications and cancer
- Breast Cancer Treatment Studies
- Cancer-related molecular mechanisms research
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Cancer, Lipids, and Metabolism
- Cell Adhesion Molecules Research
- Chronic Lymphocytic Leukemia Research
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
Centro di Riferimento Oncologico
2019-2025
miR-223 is an anti-inflammatory miRNA that in cancer acts either as oncosuppressor or oncopromoter, a context-dependent manner. In breast cancer, we demonstrated it dampens the activation of EGF pathway. However, little known on role during onset and progression. expression was decreased luminal HER2 subtypes inversely correlated with patients' prognosis. normal mammary epithelial cells, acted cell autonomously control their growth morphology three-dimensional context. MMTV-Δ16HER2...
Abstract The extracellular matrix (ECM) is an important component of the tumor microenvironment and undergoes extensive remodeling during both initiation progression breast cancer (BC). EMILIN1 ECM glycoprotein, whose function has been linked to metastasis. However, role mammary gland BC development never investigated. In silico molecular analyses human samples from normal showed that expression was lower in tumors than healthy tissue it predicted poor prognosis, particularly HER2-positive...
Breast cancer ranks as the most prevalent form of globally. Currently, advanced screening methods have significantly improved early detection rates. These achievements led to more non-invasive diagnoses and underscored clinical relevance precursor lesions like flat epithelial atypia (FEA), a histological condition characterized by mild atypical changes in normal epithelium lining mammary ducts. Despite increasing FEA biopsy, our understanding biological behavior this entity remains limited...
Abstract The CDKN1B gene, encoding for the CDK inhibitor p27 kip1 , is mutated in defined human cancer subtypes, including breast, prostate carcinomas and small intestine neuroendocrine tumors. Lessons learned from tumors suggest that mutations could be subclonal, raising question of whether a deeper sequencing approach lead to identification higher numbers patients with mutations. Here, we addressed this analyzed biopsies breast ( n = 396), ovarian 110) head neck squamous carcinoma 202)...
Abstract Breast cancer (BC) is marked by significant genetic, morphological and clinical heterogeneity. To capture this heterogeneity unravel the molecular mechanisms driving tumor progression drug resistance, we established a comprehensive patient‐derived xenograft (PDX) biobank, focusing particularly on luminal (estrogen receptor, ER+) young premenopausal patients, for whom PDX models are currently scarce. Across all BC subtypes, our efforts resulted in an overall success rate of 17% (26...
Abstract In colorectal cancer, mutation of KRAS (RAS MUT ) reduces therapeutic options, negatively affecting prognosis the patients. this setting, administration CDK4/6-inhibitors, alone or in combination with other drugs, is being tested as promising strategy. Identifying sensitive patients and overcoming intrinsic acquired resistance to CDK4/6 inhibition represent still open challenges, obtain better clinical responses. Here, we investigated role CDK inhibitor p27 kip1 response selective...
Abstract Background: Breast cancer (BC) in young women (Y) is a distinct entity terms of prognosis. Although triple negative and HER2 positive subtypes are enriched Y patients, the hormone receptor (HR) subtype (luminal, LBC) remains most common. A thorough understanding LBC biology has not been reached yet, also hampered by lack appropriate models that faithfully recapitulate these tumors molecular preclinical studies. Methods: To investigate determinants progression therapeutic resistance,...
<p>Supplementary Information, Methods and Figures. Supplementary Figure 1. Loss of miR-223 does not alter the murine mammary gland architecture; 2. KO mice do display any proliferative advantage during â^†16HER2-driven tumorigenesis; 3. WT â^†16HER2 tumor-derived epithelial cells (mMECs) comparable tumorigenic potential; 4. partially counteracts HER2-driven BC cell proliferation 3D-organization; 5. is rapidly down-modulated transformation; 6. upregulated in response to...
<div>Abstract<p>miR-223 is an anti-inflammatory miRNA that in cancer acts either as oncosuppressor or oncopromoter, a context-dependent manner. In breast cancer, we demonstrated it dampens the activation of EGF pathway. However, little known on role miR-223 during onset and progression. expression was decreased luminal HER2 subtypes inversely correlated with patients' prognosis. normal mammary epithelial cells, acted cell autonomously control their growth morphology...
<div>Abstract<p>miR-223 is an anti-inflammatory miRNA that in cancer acts either as oncosuppressor or oncopromoter, a context-dependent manner. In breast cancer, we demonstrated it dampens the activation of EGF pathway. However, little known on role miR-223 during onset and progression. expression was decreased luminal HER2 subtypes inversely correlated with patients' prognosis. normal mammary epithelial cells, acted cell autonomously control their growth morphology...
<p>Supplementary Information, Methods and Figures. Supplementary Figure 1. Loss of miR-223 does not alter the murine mammary gland architecture; 2. KO mice do display any proliferative advantage during â^†16HER2-driven tumorigenesis; 3. WT â^†16HER2 tumor-derived epithelial cells (mMECs) comparable tumorigenic potential; 4. partially counteracts HER2-driven BC cell proliferation 3D-organization; 5. is rapidly down-modulated transformation; 6. upregulated in response to...